Goserelin

Goserelin, or goserelin acetate, is a drug used to suppress production of the sex hormones, particularly in the treatment of breast and prostate cancer.

Goserelin

Goserelin; Zoladex; Goserelin acetate; Decapeptide I.

Zoladex, Zoladex-La

(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)

NA

Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.

NA

Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.

Vaginal bleeding and dryness, arthralgia, paraesthesias, increase in menstrual bleeding, hot flushes, sexual dysfunction. Headache, emotional lability, depression, insomnia, diaphoresis, dizziness, breast swelling/tenderness, Inj site reactions. Anaphylaxis.

NA

Hypersensitivity; pregnancy, lactation

Store below 25°C

Molecular weight

1269.4105

Molecular formula

C59H84N18O14

CAS number

65807-02-5

Precautions

• Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women.
• Contraceptive measures should be taken to protect against pregnancy.
• At risk from tumors flare during the 1st month of therapy will be monitored in men.
• Safety and efficacy on the usage of the 10.8 mg implant in women is not established.